Respiratory Research

Table 5 Results of regression analyses for the comorbidities in the secondary analysis

From: Quality of life assessment in interstitial lung diseases:a comparison of the disease-specific K-BILD with the generic EQ-5D-5L

			K-BILD
	EQ-5D EBVS	VAS	Total	Breathlessness	Chest symptoms	Psychological impact
	Est.	Est.	Est.	Est.	Est.	Est.
Comorbidities
Pulmonary hypertension	−0.02	2.99	2.43	1.74	5.71	3.33
Arterial hypertension	−0.05*	−2.96	−2.75	−6.85*	−1.04	− 2.08
Coronary heart disease	−0.02	−4.70	−2.06	− 2.90	−5.97	− 2.51
Congestive heart failure	0.05	−4.57	2.12	3.22	3.81	1.81
Other CVD	0.02	10.96	4.07	0.98	16.60	5.34
Diabetes mellitus	−0.03	−0.96	−1.89	0.35	−3.94	−1.91
Emphysema/COPD	−0.06	− 3.02	− 3.18	−6.03	−9.11	−2.38
Lung cancer	0	0	0	0	0	0
Depression	−0.08	−5.27	−5.36	−5.69	−17.04**	−5.87
GERD	0.04	−6.87	−0.86	−1.72	−4.39	−2.62
Renal failure	0.08	2.83	3.79	8.87	6.28	1.82
OSAS	−0.05	−6.11	−1.71	−3.66	−8.22	−1.44
Thromboembolism	−0.11	−2.82	−2.27	0.31	−9.70	−4.93
Malignant tumor	−0.01	−13.66	−0.68	3.60	−13.06	−1.28

Values depicted are the beta estimates of regression coefficients,all adjusted for age, sex, education, employment,clinic location, smoking status, FVC % pred, DLCO % pred, disease suptype. Abbreviations Est-estimates, IPF idiopathic pulmonary fibrosis, HP: hypersensitivity pnemonitis ¹including: non-specific interstitial pneumonia, desquamative interstitial pneumonia, cryptogenetic organizing pneumonia, lymphocytic interstitial pneumonia,respiratory bronchiolitis associated interstitial lung disease, pleuropulmonary fibroelastosis, and acute interstitial pneumonia. *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001

Back to article page

ISSN: 1465-993X

Contact us

General enquiries: journalsubmissions@springernature.com